Accelr8 Extends Agreement for Evaluation of BACcel System

The company did not name its partner who is assessing the system, but had a deal with Novartis that was set to expire on June 30.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.